title: Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
abstract: BACKGROUND
  In this retrospective study, we compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers.
  
  
  METHODS
  Consecutive PD patients were recruited between 2004 and 2011. Disease progression of carriers versus noncarriers was compared using survival analysis, where the end-point was the time from PD onset to reaching Hoehn and Yahr stage 3 (HY3).
  
  
  RESULTS
  Overall, 405 AJ PD patients (males = 241[60%]) were genotyped, of whom 60 (males = 30) were LRRK2*G2019S mutation carriers. Time to HY3 did not differ significantly between mutation carriers and noncarriers (hazard ratio = 1.21, 95%CI = 0.83-1.77, P = 0.33). Age at PD onset was younger for carriers than for noncarriers (59.1 ± 9.8 vs. 63.2 ± 12.0 years, respectively; P = 0.005). In both groups, young age at onset was strongly associated with longer time to HY3, (P < 0.001).
  
  
  CONCLUSIONS
  The LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in AJ PD patients.
authors.affiliation: The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Gilad
authors.initials: G
authors.lastname: Yahalom
authors.forename: Yael
authors.initials: Y
authors.lastname: Orlev
authors.forename: Oren S
authors.initials: OS
authors.lastname: Cohen
authors.forename: Evgenia
authors.initials: E
authors.lastname: Kozlova
authors.forename: Eitan
authors.initials: E
authors.lastname: Friedman
authors.forename: Rivka
authors.initials: R
authors.lastname: Inzelberg
authors.forename: Sharon
authors.initials: S
authors.lastname: Hassin-Baer
mesh_terms: D000368:Aged; D018450:Disease Progression; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D005998:Glycine / Q000235:genetics*; D006801:Humans; D007585:Jews / Q000235:genetics; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010300:Parkinson Disease / Q000208:ethnology / Q000235:genetics* / Q000503:physiopathology*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D012189:Retrospective Studies
chemical_list: C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases; D005998:Glycine
keywords: LRRK2; Parkinson's disease; disease progression; genetic